- $7.35bn
- $6.72bn
- $36.13m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab
Brief: Merus’Presents Interim Data On Petosemtamab In Metastatic Colorectal Cancer
TD Cowen raises Genmab's TP, calls $8 bln acquisition 'good strategic' deal
Deals of the day-Mergers and acquisitions
Brief: Merus NV To Pay Genmab $240 Million Termination Fee Under Certain Conditions If Deal Falls Through - SEC Filing
Merus jumps on Genmab's $8 billion buyout deal
Live Markets: FTSE edges toward record as healthcare stocks surge
Genmab falls as it agrees to acquire Merus
Live Markets: Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down
Press Digest: Wall Street Journal - September 29
Brief: Genmab To Buy Merus For USD 8.0 Billion
Genmab to buy Dutch cancer drugmaker Merus for $8 billion (updated)
Genmab nears deal to acquire Dutch cancer drugmaker Merus, Bloomberg News reports
Brief: Genmab Is Said To Near Deal To Buy Cancer Drugmaker Merus - Bloomberg News
U.S. STOCKS ON THE MOVE-Merus NV, Copper miners, GlobalFoundries
Drugmaker Merus drops on $300 mln stock offering